Scrotal variceal bleeding during rivaroxaban therapy as alarming sign in senescent patients: A clinical case
https://doi.org/10.25207/1608-6228-2022-29-3-89-102
Abstract
Background. The past decade has witnessed the advent of direct oral anticoagulants (DOACs) into clinical practice for the prevention and treatment of venous thromboembolism, as well as stroke prevention in atrial fibrillation (AF) patients. A serious complication of anticoagulant treatment is bleeding. Randomised controlled trials have shown that the risk of already developed bleeding does not reduce upon a DOAC replacement. In such cases, the bleeding cause diagnosis and elimination are recommended instead of a anticoagulant replacement. An anticoagulant treatment can only be resumed once the elimination is completed.
Clinical Case Description. Patient K., 81 yo, was emergently admitted to a cardiology ward of the Rostov Regional Clinical Hospital with a clinical picture of bilateral pulmonary embolism of small arterial branches confirmed in multislice computed angiopulmonography. Apart from venous embolism, persistent atrial fibrillation was detected as an additional indication for DOAC treatment. A CHA2DS2-VASc risk of thrombosis was 6, HAS-BLED risk of bleeding — 2. Glomerular filtration rate at bleeding was 90 mL/min/1.73 m2. The patient was prescribed rivaroxaban at 20 mg daily. Past 2 years and 3 months, rivaroxaban has been withdrawn due to bleeding developing from scrotal veins. An urologist examination revealed a bilateral spermatic cord veins dilation. A Valsalva test revealed persistent retrograde veinous blood flow. Varicocele detected on both sides.
The patient underwent venous occlusion of left internal spermatic vein following an Ivanissevich procedure. The cause of bleeding was eliminated. The patient resumed rivaroxaban 1 week since the operation.
Conclusion. The case describes a rare cause of bleeding that has been established at a continued new DOAC therapy.
About the Authors
S. A. Chepurnenko
Rostov Regional Clinical Hospital; Rostov State Medical University
Russian Federation
Russian Federation
Svetlana A. Chepurnenko — Dr. Sci. (Med.), Assoc. Prof., Chair of General Medical Practice (Family Medicine) with training in geriatrics and physiotherapy
tel.: 8 (918) 507-28-93
Nakhichevanskiy per., 19, Rostov-on-Don, 344022
Blagodatnaya str., 170, Rostov-on-Don, 344015
Nakhichevanskiy per., 29, Rostov-on-Don, 344022
G. V. Shavkuta
Rostov State Medical University
Russian Federation
Russian Federation
Galina V. Shavkuta — Dr. Sci. (Med.), Prof., Head of the Chair of General Medical Practice (Family Medicine) with training in geriatrics and physiotherapy
Nakhichevanskiy per., 29, Rostov-on-Don, 344022
A. D. Nasytko
Rostov State Medical University
Russian Federation
Russian Federation
Alina D. Nasytko — Laboratory Assistant, Chair of General Medical Practice (Family Medicine) with training in geriatrics and physiotherapy
Nakhichevanskiy per., 29, Rostov-on-Don, 344022
References
1. Kirchhof P., Haas S., Amarenco P., Hess S., Lambelet M., van Eickels M., Turpie A.G.G., Camm A.J.; XANTUS Investigators*. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. J. Am. Heart. Assoc. 2020; 9(5): e009530. DOI: 10.1161/JAHA.118.009530
2. Eerenberg E.S., Middeldorp S., Levi M., Lensing A.W., Büller H.R. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of thrombosis and haemostats. 2015; 13: 1590– 1596. DOI: 10.1111/jth.13051
3. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D., Camm A.J., Weitz J.I., Lewis B.S., Parkhomenko A., Yamashita T., Antman E.M. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383: 955–962. DOI: 10.1016/S0140-6736(13)62343-0
4. Sakuma I., Uchiyama S., Atarashi H., Inoue H., Kitazono T., Yamashita T., Shimizu W., Ikeda T., Kamouchi M., Kaikita K., Fukuda K., Origasa H., Shimokawa H. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. Heart Vessels. 2019; 34: 1839–1851. DOI: 10.1007/s00380-019-01425-x
5. Peacock W.F., Tamayo S., Sicignano N., Hopf K.P., Yuan Z., Patel M. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. Am. J. Cardiol. 2017; 119(5): 753–759. DOI: 10.1016/j.amjcard.2016.11.023
6. Søgaard M., Nielsen P.B., Skjøth F., Kjaeldgaard J.N., Larsen T.B. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. Cancer Med. 2019; 8(3): 1044–1053. DOI: 10.1002/cam4.1997
7. Khan F., Huang H., Datta Y.H. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J. Thromb. Thrombolysis. 2016; 42(4): 573–578. DOI: 10.1007/s11239-016-1410-z
8. Ellis M.H., Neuman T., Bitterman H., Dotan S.G., Hammerman A., Battat E., Eikelboom J.W., Ginsberg J.S., Hirsh J. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. Eur. J. Intern. Med. 2016; 33: 55-59. DOI: 10.1016/j.ejim.2016.05.023
9. de Vries T.I., Eikelboom J.W., Bosch J., Westerink J., Dorresteijn J.A.N., Alings M., Dyal L., Berkowitz S.D., van der Graaf Y., Fox K.A.A., Visseren F.L.J. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. Eur. Heart. J. 2019; 40(46): 3771а–3778a. DOI: 10.1093/eurheartj/ehz404
10. Dawwas G.K., Brown J., Dietrich E., Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet. Haematol. 2019; 6(1): e20– e28. DOI: 10.1016/S2352-3026(18)30191-1
11. Das U.N. A Novel Embolization Technique to Stem Hemorrhage Complications and Cancer. Balkan. Med. J. 2020; 37(4): 182–183. DOI: 10.4274/balkanmedj.galenos.2020.2020.3.109
12. Khorsand N., Majeed A., Sarode R., Beyer-Westendorf J., Schulman S., Meijer K. Subcommittee on Control of Anticoagulation. Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. J. Thromb. Haemost. 2016; 14(1): 211–214. DOI: 10.1111/jth.13148
13. Lee V.W., Tsai R.B., Chow I.H., Yan B.P., Kaya M.G., Park J.W., Lam Y.Y. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. BMC Cardiovasc. Disord. 2016; 16(1): 167. DOI: 10.1186/s12872-016-0351-y
14. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., Califf R.M.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365(10): 883–891. DOI: 10.1056/NEJMoa1009638
15. Cannon C.P., Gropper S., Bhatt D.L., Ellis S.G., Kimura T., Lip G.Y., Steg P.G., Ten Berg J.M., Manassie J., Kreuzer J., Blatchford J., Massaro J.M., Brueckmann M., Ferreiros Ripoll E., Oldgren J., Hohnloser S.H.; RE-DUAL PCI Steering Committee and Investigators. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin. Cardiol. 2016; 39(10): 555– 564. DOI: 10.1002/clc.22572
16. Wang H., Zhu B., Yu L., Li Q., Li S., Wang P., Jing T., Men T. Lycopene Attenuates Hypoxia-Induced Testicular Injury by Inhibiting PROK2 Expression and Activating PI3K/AKT/mTOR Pathway in a Varicocele Adult Rat. Evid. Based. Complement. Alternat. Med. 2021; 2021: 3471356. DOI: 10.1155/2021/3471356
17. Sack B.S., Schäfer M., Kurtz M.P. The Dilemma of Adolescent Varicoceles: Do They Really Have to Be Repaired? Curr. Urol. Rep. 2017; 18(5): 38. DOI: 10.1007/s11934-017-0686-7
18. Minaev S.V., Bolotov Yu.N. Diagnosis and treatment children with acute scrotal pain. Twenty years single centre experience. Medical News of North Caucasus. 2015; 10(2): 117–120. DOI:10.14300/mnnc.2015.10026
19. Xu C., Xia W., Sun Y., Chen H., Song T. Positive effects of the inclusion of open-mouth pressure for elimination of blood in microscopic subinguinal varicocelectomy. Int. Urol. Nephrol. 2019; 51(11): 1933–1939. DOI: 10.1007/s11255-019-02228-9
20. Kapto A.A., Zhukov O.B. Varicose veins of the small pelvis in men (literature review). Andrology and genital surgery. 2016; 2(17): 10–19 (In Russ.). DOI: 10.17650/2070-9781-2016-17-2-10-19
21. Shamsiev А.М., Kodirov N.D., Baybekov I.М., Shamsiev J.А., Tereshchenko O.A. Morphologic evolution of the dilated spermatic veins in children with varicocele. Medical News of North Caucasus. 2018; 13(3): 517– 519. DOI: 10.14300/mnnc.2018.13094
22. Broe M.P., Ryan J.P.C., Ryan E.J., Murphy D.J., Mulvin D.W., Cantwell C., Brophy D.P. Spermatic vein embolization as a treatment for symptomatic varicocele. Can. Urol. Assoc. J. 2021; 15(11): E569–E573. DOI: 10.5489/cuaj.7077
23. Niu Y., Wang D., Chen Y., Pokhrel G., Xu H., Wang T., Wang S., Liu J. Comparison of clinical outcome of bilateral and unilateral varicocelectomy in infertile males with left clinical and right subclinical varicocele: A meta-analysis of randomised controlled trials. Andrologia. 2018; 50(9): e13078. DOI: 10.1111/and.13078
Supplementary files
Review
For citations:
Chepurnenko S.A., Shavkuta G.V., Nasytko A.D. Scrotal variceal bleeding during rivaroxaban therapy as alarming sign in senescent patients: A clinical case. Kuban Scientific Medical Bulletin. 2022;29(3):89-102. (In Russ.) https://doi.org/10.25207/1608-6228-2022-29-3-89-102
Views:
1867
Email this article 